KalVista Pharmaceuticals, Inc. (KALV) Thursday reported higher loss for the second quarter, on higher research and development expenses. The loss was wider than expected.
Quarterly loss widened to $27.7 million or $0.80 per share from $22.3 million or $0.90 per share last year.
On average, five analysts polled by Thomson Reuters had expected a loss of $0.79 per share for the quarter. Analysts' estimates typically exclude special items.
The company reported no revenues for the period.
On Wednesday, KalVista shares closed at $8.97, up 0.56% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.